Regencell Bioscience Holdings Retained Earnings (Accumulated Deficit) 2020-2024 | RGC

Regencell Bioscience Holdings retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $-0.022B, a 715.43% increase year-over-year.

  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2024 were $-0.022B, a 24.85% increase from 2023.
  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2023 were $-0.017B, a 51.3% increase from 2022.
  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2022 were $-0.011B, a 186.24% increase from 2021.

Regencell Bioscience Holdings Retained Earnings (Accumulated Deficit) 2020-2024 | RGC

  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2024 were $-0.022B, a 24.85% increase from 2023.
  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2023 were $-0.017B, a 51.3% increase from 2022.
  • Regencell Bioscience Holdings retained earnings (accumulated deficit) for 2022 were $-0.011B, a 186.24% increase from 2021.